일 대학병원 정신건강의학과 병동에서의 비정형 항정신병제 처방 경향 : 11년 관찰 연구 = Prescription Pattern of Atypical Antipsychotics in a University Psychiatric Ward : 11-Year Observational Study

다국어 초록 (Multilingual Abstract)

Objectives : This study investigated the prescribing patterns of atypical antipsychotics for the various psychiatric disorders in the psychiatric ward of a University hospital.
Methods : We reviewed the medical records of patients who were discharged from an open psychiatric ward from May, 2003 through April, 2014. The association between psychiatric disorders and prescription pattern of atypical antipsychotics was analyzed.
Results : The study included 3091 patients’ prescription of psychiatric medication. 60% of prescription included antipsychotics; quetiapine was the most frequently prescribed antipsychotics, but the average dosage was the lowest among all the atypical antipsychotics.
According to the diagnoses, prescription rates and dosage of antipsychotics were different. Prescription rates of antipsychotics were the lowest in patients with anxiety disorders, and the mean dosage were the lowest in those with delirium, dementia, and amnestic and other cognitive disorders.
Conclusion : This observational study shows prescription patterns of atypical antipsychotics for the treatment of psychiatric disorders in a University hospital; atypical antipsychotics were widely used for the treatment of the various disorders, and there were differences in prescription patterns for each disorders. The results of this study may be used to identify the proper atypical antipsychotics effective on certain psychiatric disorders and to propose expanding the indications of each atypical antipsychotics in the future.

참고문헌 (Reference)

1 변선정, "정신건강의학과 개방병동 입원 환자의 진단군별 약물 처방 경향 변화 : 경기도 소재 일 대학병원에서의 11년 비교 연구" 대한생물정신의학회 22 (22): 195-204, 2015

2 권준수, "일 대학병원에서 정신분열병 외래환자의 약물사용 경향" 대한신경정신의학회 42 (42): 683-690, 2003

3 Thomas CS, "Which atypical antipsychotic?" 172 : 9-, 1998

4 Rothbard AB, "Trends in the rate and type of antipsychotic medications prescribed to persons with schizophrenia" 29 : 531-540, 2003

5 Bret MC, "The use of atypical antipsychotics in French psychiatric hospitals" 29 : 551-556, 2007

6 Maher AR, "Summary of the comparative effectiveness review on off-label use of atypical antipsychotics" 18 : 1-20, 2012

7 Maher AR, "Summary of the comparative effectiveness review on off-label use of atypical antipsychotics" 18-, 2012

8 Migler BM, "Seroquel: behavioral effects in conventional and novel tests for atypical antipsychotic drug" 112 : 299-307, 1993

9 Scherk H, "Second-generation antipsychotic agents in the treatment of acute mania: a systematic review and meta-analysis of randomized controlled trials" 64 : 442-455, 2007

10 Lucey JV, "Risperidone compared with olanzapine in a naturalistic clinical study in Ireland: a cost analysis" 172 : 195-201, 2003

11 Kasper S, "Risperidone Olanzapine Drug Outcomes studies in Schizophrenia (RODOS): Efficacy and tolerability results of an international naturalistic study" 16 : 179-187, 2001

12 Taylor DM, "Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia UKIG. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis" 64 : 589-597, 2003

13 Schneider LS, "Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials" 294 : 1934-1943, 2005

14 McManus DQ, "Quetiapine, a novel antipsychotic: experience in elderly patients with psychotic disorders" 60 : 292-298, 1999

15 Smith LA, "Pharmacological interventions for acute bipolar mania: a systematic review of randomized placebo-controlled trials" 9 : 551-560, 2007

16 Diatta T, "Patterns and frequency of atypical antipsychotic prescribing in psychiatric medical centers: a cross-sectional national survey" 21 : 371-378, 2007

17 Volavka J, "Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol" 24 : 225-228, 2004

18 Maglione M, "Off-label use of atypical antipsychotics: an update" 2011

19 Kerwin R, "New antipsychotics" 6 : 71-82, 1996

20 Olfson M, "National trends in the office-based treatment of children, adolescents, and adults with antipsychotics" 69 : 1247-1256, 2012

21 Gardner DM, "International consensus study of antipsychotic dosing" 167 : 686-693, 2010

22 Danion JM, "Improvement of schizophrenic patients with primary negative symptoms treated with amisulpride" 156 : 610-616, 1999

23 Lecrubier Y, "Improvement by amisulpride of the negative syndrome in non-psychotic subjects: A preliminary study" 3 : 329-333, 1988

24 Miller DD, "Extrapyramidal side-effects of antipsychotics in a randomised trial" 193 : 279-288, 2008

25 McEvoy JP, "Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison" 164 : 1050-1060, 2007

26 Maher AR, "Efficacy and comparative effectiveness of atypical antipsychotic medications for off-label uses in adults: a systematic review and meta-analysis" 306 : 1359-1369, 2011

27 McDonagh M, "Drug class review: atypical antipsychotic drugs" 2010

28 Sultzer DL, "Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease:phase 1 outcomes from the CATIE-AD effectiveness trial" 165 : 844-854, 2008

29 Crystal S, "Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges" 28 : w770-w781, 2009

30 Krakowski MI, "Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder" 63 : 622-629, 2006

31 Keck PE, "Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study" 112 : 36-49, 2009

32 Young AH, "Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study" 194 : 40-48, 2009

33 Rapoport M, "Antipsychotic use in the elderly: shifting trends and increasing costs" 20 : 749-753, 2005

34 Verdoux H, "Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies" 121 : 4-10, 2010

35 Dolder CR, "Antipsychotic medication adherence: is there a difference between typical and atypical agents?" 159 : 103-108, 2002

36 Lecrubier Y, "Amisulpride versus imipramine and placebo in dysthymia and major depression" 43 : 95-103, 1997

37 Jeste DV, "ACNP White Paper: update on use of antipsychotic drugs in elderly persons with dementia" 33 : 957-970, 2008

38 Snaterse M, "A retrospective, naturalistic review comparing clinical outcomes of in-hospital treatment with risperidone and olanzapine" 20 : 159-164, 2000

39 Matsunaga H, "A long-term trial of the effectiveness and safety of atypical antipsychotic agents in augmenting SSRI-refractory obsessive-compulsive disorder" 70 : 863-868, 2009

40 Maina G, "8-week, single-blind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder" 18 : 364-372, 2008